Skip to main content
. 2017 Jun 16;14(2):2053–2058. doi: 10.3892/ol.2017.6397

Figure 1.

Figure 1.

(A) Representative images of TXNIP immunohistochemical staining by treatment with DAB chromogen and hematoxylin in (A-a) WHO grade I gliomas, (A-b) WHO grade II gliomas, (A-c) WHO grade III gliomas and (A-d) WHO grade IV gliomas. The expression level of TXNIP was significantly decreased in higher grade tumors (P<0.05). (B) The relative expression of TXNIP mRNA detected by reverse transcription-quantitative polymerase chain reaction. The expression level of TXNIP mRNA was significantly decreased in higher grade tumors. (C) The association of TXNIP expression with the overall survival of glioma patients. WHO, World Health Organization; TXNIP, thioredoxin-interacting protein.